Alzheimer's biotech comes under attack as petition calls for trial halt, data audit — and it's fighting back
Little Cassava Sciences has complete faith in its experimental Alzheimer’s drug. Ever since pivoting away from a four-time reject analgesic (and from its former identity as Pain Therapeutics), the biotech has plowed steadily away at clinical trials for a new lead program called simufilam, plotting major Phase III trials and significant investment into the neurodegenerative disease — even before the FDA approval of Biogen’s Aduhelm reinvigorated the entire field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.